IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 2 biotech developing a novel norovirus vaccine in-licensed from Takeda.
Industry: Health Care
Latest Trade: $12.58 0.00 (0.0%)
First Day Return: +12.3%
Return from IPO: -26.0%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 04/06/2022 |
Offer Price | $17.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 11.8 |
Deal Size ($mm) | $200 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 04/28/2022 |
Offer Price | $17.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 11.8 |
Deal Size ($mm) | $200 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
J.P. Morgan |
Leerink Partners |
more |
Company Data | |
---|---|
Headquarters | Boston, MA, United States |
Founded | 2019 |
Employees | 31 |
Website www.hillevax.com |